Company intelligence / Profile preview

Perall

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Perall is a clinical-stage biotechnology company dedicated to developing transformative therapies for food allergies. The company utilizes a proprietary platform designed to provide personalized and precise treatment options, moving beyond traditional desensitization methods. Its lead programs focus on common and severe allergens, such as peanut allergy, aiming to improve patient safety and quality of life. By leveraging advanced immunological insights, Perall seeks to redefine the standard of care for individuals living with life-threatening food sensitivities.

Therapeutic areas: Immunology
Modalities: Small moleculeBiologicPeptides
Industry: Biotech

Beyond the preview

Go deeper on Perall.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perall.

Explore the full profile